Floatz logo

cd3-depleted/cd56+ selected natural killer cells collected from apheresis products

Neuroblastoma

University Hospital, Basel, SwitzerlandCell therapyPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
81/ 100

Competitive context

63 Active assets in the Neuroblastoma cohort.

Asset / SponsorPhaseRating
Irinotecan
National Cancer Institute (NCI)
Phase 2BB
ETOPOSIDE
M.D. Anderson Cancer Center
Phase 2/3BB
FILGRASTIM
M.D. Anderson Cancer Center
Phase 4BB
Eloxatin
National Cancer Institute (NCI)
Phase 2BB
Cyclophosphamide
Robbie Majzner
Phase 2BB

View all 50 →

Same molecule, other indications

cd3-depleted/cd56+ selected natural killer cells collected from apheresis products is also rated in:

acute myeloid leukemiaDormant
CCC
Indicative ·
48 / 100
View asset →
precursor lymphoblastic lymphoma/leukemiaDormant
CCC
Indicative ·
48 / 100
View asset →
rhabdomyosarcomaDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →